S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:FATE

Fate Therapeutics - FATE Stock Forecast, Price & News

$32.84
-1.30 (-3.81%)
(As of 08/9/2022 05:24 PM ET)
Add
Compare
Today's Range
$31.37
$33.52
50-Day Range
$17.78
$34.14
52-Week Range
$17.10
$97.43
Volume
1.50 million shs
Average Volume
1.46 million shs
Market Capitalization
$3.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.42

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
129.6% Upside
$75.42 Price Target
Short Interest
Bearish
23.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.30mentions of Fate Therapeutics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.40) to ($4.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

699th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

109th out of 174 stocks

FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on FATE shares. Truist Financial dropped their target price on shares of Fate Therapeutics from $125.00 to $75.00 in a research report on Wednesday, April 13th. Piper Sandler lowered their target price on shares of Fate Therapeutics from $113.00 to $71.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. Robert W. Baird began coverage on shares of Fate Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $28.00 price objective for the company. Needham & Company LLC began coverage on shares of Fate Therapeutics in a research note on Thursday, July 28th. They issued a "hold" rating for the company. Finally, BMO Capital Markets upgraded shares of Fate Therapeutics from a "market perform" rating to an "outperform" rating and reduced their price objective for the company from $50.00 to $47.00 in a research note on Monday, July 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $75.42.

Fate Therapeutics Price Performance

FATE traded down $2.70 during trading on Tuesday, hitting $31.44. 64,119 shares of the company's stock were exchanged, compared to its average volume of 1,165,866. The stock has a 50 day moving average price of $27.12 and a 200 day moving average price of $31.34. Fate Therapeutics has a 1 year low of $17.10 and a 1 year high of $97.43.

Insiders Place Their Bets

In other Fate Therapeutics news, Director John Mendlein sold 1,364 shares of the company's stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $22.79, for a total transaction of $31,085.56. Following the completion of the sale, the director now directly owns 158,091 shares of the company's stock, valued at $3,602,893.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director John Mendlein sold 1,364 shares of the stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the transaction, the director now owns 158,091 shares in the company, valued at $3,602,893.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO J Scott Wolchko sold 30,000 shares of the firm's stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $32.88, for a total value of $986,400.00. Following the completion of the transaction, the chief executive officer now directly owns 431,546 shares of the company's stock, valued at $14,189,232.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,082 shares of company stock valued at $1,646,106. Company insiders own 18.58% of the company's stock.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Fate Therapeutics (NASDAQ:FATE) PT Lowered to $90.00
Fate Therapeutics: Q2 Earnings Insights
Expert Ratings for Fate Therapeutics
Tuesday's ETF Movers: ARKK, OIH
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$75.42
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+129.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-212,150,000.00
Net Margins
-371.73%
Pretax Margin
-371.73%

Debt

Sales & Book Value

Annual Sales
$55.85 million
Book Value
$7.11 per share

Miscellaneous

Free Float
78,977,000
Market Cap
$3.19 billion
Optionable
Optionable
Beta
1.62














FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FATE shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2022?

12 analysts have issued 1 year price targets for Fate Therapeutics' stock. Their FATE share price forecasts range from $28.00 to $115.00. On average, they predict the company's share price to reach $75.42 in the next year. This suggests a possible upside of 136.1% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How has Fate Therapeutics' stock price performed in 2022?

Fate Therapeutics' stock was trading at $58.51 at the start of the year. Since then, FATE shares have decreased by 45.4% and is now trading at $31.94.
View the best growth stocks for 2022 here
.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.13. The biopharmaceutical company earned $14.23 million during the quarter, compared to the consensus estimate of $8.67 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 40.37% and a negative net margin of 371.73%. The firm's revenue was up 88.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.36) earnings per share.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.87%), Pictet Asset Management SA (2.17%), Sumitomo Mitsui Trust Holdings Inc. (1.31%), Nikko Asset Management Americas Inc. (1.31%), Victory Capital Management Inc. (1.11%) and Brown Advisory Inc. (0.51%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $31.94.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $3.10 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.